Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03125408 · ClinicalTrials.gov registry record
Clinical Performance Evaluation of DxN HCV Assay
A clinical trial, sponsored by Beckman Coulter.
- Terminated
- Registry status
- 210
- Enrollment target
NCT03125408: Clinical Trial study, sponsored by Beckman Coulter.
NCT03125408 is a clinical trial that was terminated before completion, run by Beckman Coulter. The registered enrollment target is 210 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03125408 was terminated before completion, sponsored by Beckman Coulter.
- TERMINATED
- Registry status
- 210 participants
- Enrollment target
Study Summary
The DxN Hepatitis C Virus (HCV) Assay is an in vitro diagnostic assay intended as an aid in the management of of HCV-infected individuals undergoing antiviral therapy. The purpose of the study is to establish the clinical performance of the DxN HCV Assay for plasma samples in the intended use population.
Primary Outcome
Defined as unquantifiable HCV Viral load after discontinuation of therapy
Interventions
- DIAGNOSTIC_TEST HCV Assay
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2012-05-02 |
| Est. Completion | 2017-08-30 |
Why NCT03125408 stopped before completion
NCT03125408 is an observational study that tracks outcomes without assigning an intervention. The registered 210 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which HCV Assay is the first listed.
NCT03125408 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03125408 about?
NCT03125408 is a clinical study titled "Clinical Performance Evaluation of DxN HCV Assay". The DxN Hepatitis C Virus (HCV) Assay is an in vitro diagnostic assay intended as an aid in the management of of HCV-infected individuals undergoing antiviral therapy. The purpose of the study is to establish the clinical performance of the DxN HCV Assay for plasma samples in the intended use popula...
What is the current status of trial NCT03125408?
This trial is currently terminated. The enrollment target is 210 participants. The study started on 2012-05-02. Estimated completion is 2017-08-30.
What interventions are being tested in trial NCT03125408?
The interventions under investigation include: HCV Assay (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03125408?
This trial is sponsored by Beckman Coulter, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02665923 · 210 participants
Gastric Emptying in Neonates and Infants After Formula Feeding
- NCT03322891 · 210 participants · NA
Improving Health Literacy in African-American Prostate Cancer Patients
- NCT03544489 · 210 participants · Phase 2
Effectiveness of Exercise After an ICD
- NCT04408430 · 210 participants · NA
The MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI